[CAS NO. 186611-52-9] IC261
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [186611-52-9]
Store
Catalog
SLK-S8237
Brand
Selleck
CAS
186611-52-9
DESCRIPTION [186611-52-9]
Overview
| MDL | MFCD00118156 |
|---|---|
| Molecular Weight | 311.33 |
| Molecular Formula | C18H17NO4 |
| SMILES | O=C1NC2=C(C=CC=C2)/C1=C\C3=C(OC)C=C(OC)C=C3OC |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2120 mL | 16.0601 mL | 32.1203 mL |
| 5 mM | 0.6424 mL | 3.2120 mL | 6.4241 mL |
| 10 mM | 0.3212 mL | 1.6060 mL | 3.2120 mL |
| 50 mM | 0.0642 mL | 0.3212 mL | 0.6424 mL |
Description
IC261 (SU-5607) is a novel inhibitor of . The IC50 of IC261 for CK1 is 16 μM and for Cdk5 is 4.5 mM.
Targets
| CK1 [4] |
| 16 μM |
In vitro
IC261 leads to a p53-dependent arrest of the cells with a DNA content of 4 N. It can produce effects on cell cycle progression that are indistinguishable from an established spindle poison and are dependent on the p53 status of the cells.
In vivo
Intrathecal injection of a CK1 inhibitor IC261 attenuates neuropathic pain behaviors. CK1 inhibitors are found to be effective in reducing spinal excitatory response elicited by the presynaptic electrical stimulation only in neuropathic mice. Targeting CK1 isoforms by IC261 influences both pancreatic tumour cell growth and apoptosis sensitivity in vitro and the growth of induced tumours in vivo.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.